The month of March has been very busy for PARADIGM. On 7 and 8 of March, members of WP1 and WP2 met in Oxford for a two-day workshop. Over the first year of PARADIGM, WP1 has been looking at the needs, preferences and expectations of the different stakeholders involved in patient engagement (PE) in the process of developing medicines. The workshop in Oxford focused on how to incorporate the findings of the work carried out by WP1 (online survey, consultations and Delphi study) into the gap analysis which WP2 is conducting. Later on, at the end of the month (27-28 March) a second set of PARADIGM workshops were organised in Berlin. During the first day, delegates discussed about the impact of PE, and how such impact, could be monitored and assessed (work led by WP3). Delegates had the opportunity to learn about the framework that members of WP3 have developed for assessing the impact of patient engagement in the context of PARADIGM. One of the examples to test out the framework was a case presented by Alzheimer Europe linked to work of the EWGPWD. Chris Roberts, vice chair of the EWGPWD and his wife, Jayne Goodrick were present in the workshop and provided very relevant input about their personal experience of being involved in PE in this, and may other activities, at European and national level. On the second day, discussions were focused on WP4 which will be developing a toolbox with tools and templates for PE in medicines development. Ana Diaz, AE project officer, Chris Roberts, vice chair of the EWGPWD and Jayne Goodrick, supporter, participated in the various workshops.